 In the Real World Effectiveness and Safety reads, study of mepalizumab in a multi-centric Spanish cohort of asthma patients, mepalizumab was found to reduce the need for oral corticosteroid, OCS, usage and decrease the number of patients requiring high dosages of OCS. As a result, approximately half of these patients would no longer require anti-osteoporotic treatments. This article was authored by Christian Domingo, Christian Domingo, Anasogo and others.